tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tianjin Pharmaceutical Provides Update on Subsidiary’s Bankruptcy Proceedings

Story Highlights
  • Tianjin Pharmaceutical Da Ren Tang operates in the pharmaceutical industry in China.
  • No significant developments in the bankruptcy proceedings of its subsidiary have been reported.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Tianjin Pharmaceutical Provides Update on Subsidiary’s Bankruptcy Proceedings

TipRanks Cyber Monday Sale

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ) has shared an announcement.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has provided an update on the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd. As of the latest update, there have been no significant developments in the bankruptcy proceedings that would impact the company’s financial position. The company remains committed to monitoring the situation closely, maintaining communication with relevant parties, and safeguarding shareholder interests. Monthly updates will continue to be provided in accordance with listing requirements.

More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is a company incorporated in the People’s Republic of China. It operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products.

Find detailed analytics on 2TZ stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1